- Home
- GERN vs PVLA Comparison
GERN vs PVLA Comparison
Compare GERN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GERN | PVLA |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GERN | PVLA |
|---|---|---|
| Price | $1.46 | $134.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 17 |
| Target Price | $2.17 | ★ $154.59 |
| AVG Volume (30 Days) | ★ 16.5M | 349.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $32.27 | N/A |
| Revenue Next Year | $60.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $18.23 |
| 52 Week High | $2.01 | $151.18 |
Technical Indicators
Market Signals| Indicator | GERN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 41.84 | 69.57 |
| Support Level | $1.20 | $85.53 |
| Resistance Level | $1.68 | N/A |
| Average True Range (ATR) | 0.16 | 8.81 |
| MACD | -0.04 | 6.30 |
| Stochastic Oscillator | 5.08 | 77.00 |
Price Performance
Historical ComparisonAbout GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.